Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium SCHEMBL30668131 | 0.98 | ALDH1A1 (0.40) | ALDH1A1MITFPKML3MBTL1KMT2A | |
| SCHEMBL9385677 | 0.84 | ALDH1A1 (0.40) | ALDH1A1MITFPKML3MBTL1KMT2A | |
| SCHEMBL30668083 | 0.84 | ALDH1A1 (0.40) | ALDH1A1MITFPKML3MBTL1KMT2A | |
| SCHEMBL5313447 | 0.81 | MITF (0.40) | ALDH1A1MITFPKML3MBTL1KMT2A | |
| SCHEMBL5231541 | 0.80 | ALDH1A1 (0.37) | ALDH1A1MITFPKML3MBTL1KMT2A | |
| SCHEMBL2445825 | 0.78 | ALDH1A1 (0.61) | ALDH1A1MITFPKML3MBTL1KMT2A | |
| SCHEMBL9385579 | 0.78 | ALDH1A1 (0.36) | ALDH1A1MITFPKML3MBTL1KMT2A | |
| SCHEMBL1594419 | 0.78 | MITF (0.52) | ALDH1A1MITFPKML3MBTL1KMT2A | |
| SCHEMBL12307516 | 0.77 | AR (0.36) | ALDH1A1MITFPKML3MBTL1KMT2A | |
| Hydrochloric Acid SCHEMBL5741754 | 0.77 | MITF (0.51) | ALDH1A1MITFPKML3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116120238-B | Preparation method of imidazole derivative | 山东梅奥华卫科技有限公司 | 2023-09-22 | — | — | CN | claimed |
| CN-116120238-A | Preparation method of imidazole derivative | 山东梅奥华卫科技有限公司 | 2023-05-16 | — | — | CN | claimed |
| CN-116120238-B | Preparation method of imidazole derivative | 山东梅奥华卫科技有限公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-116120238-B | Preparation method of imidazole derivative | 山东梅奥华卫科技有限公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-116120238-A | Preparation method of imidazole derivative | 山东梅奥华卫科技有限公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-116120238-A | Preparation method of imidazole derivative | 山东梅奥华卫科技有限公司 | 2023-05-16 | — | — | CN | disclosed |
| US-8524899-B2 | Oligopeptide containing fused 6-membered ring forming complexes with double stranded dna; complexes can be used for identification of specific dsDNA sequences, inhibiting gene transcription, therapeutic for inhibiting proliferation of undesired cells or modulation of expression of specific gene | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2013-09-03 | — | — | US | disclosed |
| EP-1599474-B1 | Heterocyclic oligomeric compounds for DNA recognition | CALIFORNIA INST OF TECHN (US) | 2013-04-24 | — | — | EP | disclosed |
| CN-101128455-B | Heterocyclylamide-substituted imidazoles | AICURIS GMBH & CO KG | 2013-01-16 | — | — | CN | disclosed |
| EP-2530078-A1 | THIAZOLE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2012-12-05 | — | — | EP | disclosed |
| US-7713701-B2 | DNA-binding polymers | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2010-05-11 | — | — | US | disclosed |
| EP-1469856-A2 | 8-HETEROARYL XANTHINE ADENOSINE A SB 2B /SB RECEPTOR ANTAGONISTS | King Pharmaceuticals Research and Development Inc. (US) | 2004-10-27 | — | — | EP | disclosed |
| WO-2004078943-A2 | ALTERNATIVE HETEROCYCLES FOR DNA RECOGNITION | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20030207879-A1 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2003-11-06 | — | — | US | disclosed |
| CN-1439006-A | Novel compounds possessing antibacterial, antifungal or antitumor activity | GENELABS TECH INC (US) | 2003-08-27 | — | — | CN | disclosed |
| WO-2003063800-A2 | 8-HETEROARYL XANTHINE ADENOSINE A2B RECEPTOR ANTAGONISTS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2003-08-07 | — | — | WO | disclosed |
| EP-0885189-A2 | METHOD FOR THE SYNTHESIS OF POLY-PYRROLE AND POLY-IMIDAZOLE CARBOXAMIDES ON A SOLID SUPPORT | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997030975-A2 | METHOD FOR THE SYNTHESIS OF POLY-PYRROLE AND POLY-IMIDAZOLE CARBOXAMIDES ON A SOLID SUPPORT | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1997-08-28 | — | — | WO | disclosed |
| WO-1994003434-A1 | IMIDAZOLE-CONTAINING ANALOGS OF DISTAMYCIN | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1994-02-17 | — | — | WO | disclosed |
| US-5273991-A | Anticarcinogenic agents | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1993-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207879-A1 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ALDH1A1 251/4885MITF 2336/4885PKM 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.